Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B
This trial is conducted in Asia, Europe, Japan, North America and South Africa. The aim is to evaluate the safety and efficacy of nonacog beta pegol (NNC-0156-0000-0009) after long-term exposure in patients with haemophilia B.
This trial is an extension to trials NN7999-3747 (NCT01333111/paradigm™ 2) and NN7999-3773 (NCT01386528/paradigm™ 3).
Inclusion Criteria:
Exclusion Criteria:
Kashihara-shi, Nara, 634 8522, Japan
Nagoya-shi, Aichi, 466 8560, Japan
Nishinomiya-shi, 663 8051, Japan
Parktown Johannesburg, Gauteng 2193, South Africa